← Leaderboards
Nicholas Restifo
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseImmunotherapyScientistSignal TransductionTranslatingCollaborationsResearch PersonnelT-LymphocyteClinical TrialsCytokineDesignAdvanced Malignant NeoplasmMediatingTumorInterleukin 2 Receptor GammaMalignant NeoplasmsCd8b1 GeneProgramsResponseAntigen TargetingIn Vitro AssayAdoptive ImmunotherapyShapesMemory
Grant awards (18)
Building on the success of the adoptive immunotherapy of cancer$3,013,441
ZIA · FY2019 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$4,924,486
ZIA · FY2018 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$2,175,777
ZIA · FY2017 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$2,303,767
ZIA · FY2016 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$2,673,969
ZIA · FY2015 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$1,572,829
ZIA · FY2014 · CA · contact PI
Developing new immunotherapies based of CD4+ T cells$774,677
ZIA · FY2014 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$1,302,115
ZIA · FY2013 · CA · contact PI
Developing new immunotherapies based of CD4+ T cells$581,621
ZIA · FY2013 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$1,556,796
ZIA · FY2012 · CA · contact PI
Developing new immunotherapies based of CD4+ T cells$766,780
ZIA · FY2012 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$1,380,074
ZIA · FY2011 · CA · contact PI
Developing new immunotherapies based of CD4 T cells$679,738
ZIA · FY2011 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$1,560,072
ZIA · FY2010 · CA · contact PI
Developing new immunotherapies based of CD4 T cells$768,394
ZIA · FY2010 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$1,782,313
ZIA · FY2009 · CA · contact PI
Developing new immunotherapies based of CD4 T cells$877,856
ZIA · FY2009 · CA · contact PI
Developing new immunotherapies based of CD4 T cells$826,167
Z01 · FY2008 · CA · contact PI